A practical and convenient method of rearing Eucyclops serrulatus in a microculture environment is described. A complete life cycle of E. serrulatus was maintained in a narrow space on a microscope slide glass on which a cover glass of 22 x 40 mm in size was mounted at a height of 0.8 mm. The culture medium was constituted by bottled mineral water boiled with grains of Glycine max (soybean). Chilomonas paramecium, a free-living protozoan organism, was provided as live food. Growth of nauplii hatched from eggs to the first stage of copepodite took an average of 7.7 days, and the growth of copepodite 1 to the egg-bearing adult female took an average of 20.1 days in the microculture cell with an average life time of 44.7 days. Continuous passage of copepods was successfully maintained as long as sufficient medium and food were provided. The microculture method enables an in situ microscopic observation on the growth and developmental process of helminth larvae experimentally infected to copepods as well as of copepod itself. Furthermore, it does not require anesthetization and, therefore, minimize the amount of stress exposed to copepods during the handling process.
Protozoa ; Male ; Female ; Culture Techniques/*methods ; Culture Media ; Copepoda/*growth & development ; Animals

BACKGROUNDS: There is difference of blood flow between right and left lung, and it is also affected by positional change. The purpose of this study is to compare hemodynamics and arterial blood gas changes between two lungs in thoracoscopic surgery with CO2 insufflation METHODS: Fourteen thoracoscopic-surgical patient were randomly selected and divided into two groups; Group I : right lung ventilation, Group II: left lung ventilation. Blood gas analysis, blood pressure and heart rate were measured at three stages in lateral position; stage I: 10minutes after two-lung ventilation, stage II: 10minutes after one-lung ventilation and CO2 insufflation, stage III: 10minutes after two-lung ventilation and CO2 deflation. RESULTS: In both groups, blood pressure and heart rate were slightly increased at stage II, pH was decreased, PaO2 and PaCO2 were increased at stage II and stage III. But changes of pH and PaCO2 were greater in left lung ventilation. Arterial oxygen saturation and base excess did not change in all stages. CONCLUSIONS: Thoracoscopic surgery with CO2 insufflation did not increase the risk of hypoxemia if FiO2 is 1.0. However blood CO2 retension is higher in left lung ventilation than in right one. So we have to observe PaCO2 more carefully when the left lung is ventilated.
Anoxia ; Blood Gas Analysis ; Blood Group Antigens ; Blood Pressure ; Heart Rate ; Hemodynamics* ; Humans ; Hydrogen-Ion Concentration ; Insufflation* ; Lung* ; One-Lung Ventilation ; Oxygen ; Thoracoscopy* ; Ventilation*

No abstract available.
Anesthesia ; Rubinstein-Taybi Syndrome

BACKGROUND: Serious pulmonary complications after lung surgery increase morbidity and mortality in perioperative period. Ketamine hydrochloride produces strong analgesic effect in spite of the psychomimetic effects. Intravenous anesthesia with ketamine was performed in lung surgery of patients with decreased pulmonary function and compared with inhalation anesthesia with enflurane. METHODS: Sixty patients, scheduled for elective lung surgery, were randomly assigned to two groups. Patients received either enflurane (Group 1, n=30) or ketamine (Group 2, n=30) as main anesthetic drug. Blood pressure and heart rate were compared in preinduction, postinduction, postintubation, postincision, intraoperative period (30 minutes, 60 minutes) and recovery room between groups, and in each group. Arterial blood gas analysis was compared in preoperative period, intraoperative period and recovery room between groups. Postoperative psychological complications evaluated in group 2. RESULTS: Blood pressure and heart rate were significantly different in postinduction, postintubation and recovery room between groups. PaO2 in group 2 was higher than in group 1 during intraoperative period and recovery room. Postoperative psychological complications occured in 4 patients (13%) in group 2. CONCLUSIONS: Ketamine affords advantage over enflurane anesthesia in terms of PaO2 during intraoperative period and recovery room in lung surgery of patients with decreased pulmonary function.
Anesthesia ; Anesthesia, Inhalation* ; Anesthesia, Intravenous* ; Blood Gas Analysis ; Blood Pressure ; Enflurane* ; Heart Rate ; Humans ; Inhalation* ; Intraoperative Period ; Ketamine* ; Lung* ; Mortality ; Perioperative Period ; Preoperative Period ; Recovery Room

Anesthesia for thoracic surgery is most commonly performed with the patient in the lateral decubitus position, with nondependent hemithorax comprising the operation field. When one-lung ventilation is employed, the nondependent lung is nonventilated and collapsed, while the dependent lung is ventilated. Consequently one-lung ventilation creates an obligatory right to left transpulmonary shunt through the nondependent nonventilated lung. Therefore one-lung ventilation results in a much larger alveolar-arterial oxygen tension-difference P(A-a)O2 and lower PaO2 than does two-lung ventilation. The present study was to evaluate oxygenation effect of selective CPAP to nondependent lung in the 17 thoracic surgical patients. Arterial blood gases were analysed, systolic blood pressures and heart rates were measured at following stages. Stage I; lateral decubitus position before chest opening Stage II; 15 min after chest opening and one lung ventilation stage III; 15 min after application of selective CPAP 5 cmHO to the nondependent lung stage IV; 40 min after application of selective CPAP 5 cmHO to the nondependent lung The results were as follows: 1) In stage II, the value of PaO2 was significantly lower as compared to that in stage I(224.9+/-78.0 vs 418.2+/-63.1 mmHg, P<0.01). 2) In stage III and IV, the values of PaC4 were significantly higher.as compared to that in stage II(333.8+/-97.1, 364.5+/-88.6 vs 224,9+/-78.0 mmHg, P<0.01). 3) In stage III, the value of PaCO2 was significantly lower as compared to that in stage II(37.1+/-2.9 vs 38.2+/-2.7 mmHg, P<0.05). 4) In stage IV, the value of pH was significantly lower as compared to that in stage III(7.37+/-0.05 vs 7.38+/-0.05 P<0.05). 5) Systolic blood pressures and heart rates remained unchanged at all times. We concluded that application of 5 cmHO CPAP to the nondependent lung during one-lung ventilation is one of most efficacious maneuvers to increase PaO2, accompanying less surgical interference.
Anesthesia ; Continuous Positive Airway Pressure* ; Gases ; Heart Rate ; Humans ; Hydrogen-Ion Concentration ; Lung* ; One-Lung Ventilation ; Oxygen* ; Thoracic Surgery ; Thorax ; Ventilation*

Buerger's disease (thromboangiitis obliterans) is an inflammatory, nonatherosclerotic, occlusive disease of small- and medium-sized arteries and veins that involves distal vessels of the extremities. Patients show symptoms related to ischemia of distal lower extremities and upper extremities (claudication, gangrene, rest pain, distal cyanosis). We report a case of progressive ascending motor weakness of the lower extremities in a Buerger's disease patient due to a metastatic bone tumor on the T3 level after lumbar epidural block and continuous cervical epidural block.
Arteries ; Extremities ; Gangrene ; Humans ; Ischemia ; Lower Extremity ; Spinal Cord Compression* ; Spinal Cord* ; Thromboangiitis Obliterans* ; Upper Extremity ; Veins

BACKGROUND: Continuous epidural morphine administration (CEM) is a common method to treat the pain of terminal cancer patients, but this could produce many side effects/ such as pruritus, nausea, vomiting, constipation and urinary retention. The purpose of this study was to determine the optimal epidural butorphanol dosage to prevent side effects of CEM in terminal cancer patients. METHODS: Thirty terminal cancer patients were randomly assigned to one of three groups. After insertion of epidural catheter, morphine 2 mg and butorphanol 1 mg were injected epidurally for a loading dose and a 2 Day Infusor (2 ml/hr)(Home Pump(R) , I-Flow, Lake Forest, USA) containing morphine 8 mg with butorphanol 2 mg (B2 group, n = 10), 4 mg (B4 group, n = 10) or 6 mg (B6 group, n = 10) mixed with 5% D/W (total 100 ml) was connected. Severity of pain, nausea and vomiting, and pruritus were evaluated using VAS score at 1, 6, 12, 24, 36 and 48 hr after epidural infusion. RESULTS: Severity of pain, nausea and vomiting, and pruritus were significantly decreased in the B6 group as comparable to the other two groups (p < 0.05). CONCLUSIONS: The addition of butorphanol 3 mg to morphine 4 mg in CEM in terminal cancer patients reduced nausea, vomiting and pruritus and improved the pain control effect.
Butorphanol* ; Catheters ; Constipation ; Humans ; Infusion Pumps ; Lakes ; Morphine* ; Nausea ; Pruritus ; Urinary Retention ; Vomiting

Intestinal Behçet's disease is a rare, immune-mediated chronic intestinal inflammatory disease; therefore, clinical trials to optimize the management and treatment of patients are scarce. Moreover, intestinal Behçet's disease is difficult to treat and often requires surgery because of the failure of conventional medical treatment. Administration of anti-tumor necrosis factor–α, a potential therapeutic strategy, is currently under active clinical investigation, and evidence of its effectiveness for both intestinal Behçet's disease and inflammatory bowel diseases has been accumulating. Here, we review updated data on current experiences and outcomes after the administration of anti-tumor necrosis factor–α for the treatment of intestinal Behçet's disease. In addition to infliximab and adalimumab, which are the most commonly used agents, we describe agents such as golimumab, etanercept, and certolizumab pegol, which have recently been shown to be effective in refractory intestinal Behçet's disease. This review also discusses safety issues associated with anti-tumor necrosis factor–α, including vulnerability to infections and malignancy.
Adalimumab ; Behcet Syndrome ; Certolizumab Pegol ; Etanercept ; Humans ; Inflammatory Bowel Diseases ; Infliximab ; Necrosis*